@article {1435397,
	title = {Oral guaifenesin for treatment of filamentary keratitis: A pilot study},
	journal = {Ocul Surf},
	year = {2019},
	month = {2019 Apr 01},
	abstract = {PURPOSE: Pilot study to evaluate the safety and efficacy of oral guaifenesin in reducing the signs and symptoms of filamentary keratitis. METHODS: Prospective, uncontrolled open-label pilot study. Twelve patients with non-Sj{\"o}gren dry eye disease (DED) and secondary filamentary keratitis received treatment with oral guaifenesin 600 mg twice a day (total dose of 1.2 g/day) for 4 weeks. Adverse events, change in the number of corneal filaments, corneal fluorescein staining (CFS; NEI grading system), and symptoms (Ocular Surface Disease Index) were assessed. RESULTS: Before starting oral guaifenesin, all patients were on topical medical therapy for their condition. At baseline, the mean number of filaments was 5.8 {\textpm} 2.9, CFS score 7.3 {\textpm} 3.2, and OSDI score 55.6 {\textpm} 25. After 4 weeks of treatment, the number of filaments was 2.1 {\textpm} 2.2 (p = 0.04 vs. baseline), CFS score 6.5 {\textpm} 3.1 (p = 0.5), and OSDI score 46.1 {\textpm} 30.9 (p = 0.2). One patient discontinued the medication due to gastrointestinal side effects. CONCLUSIONS: Oral guaifenesin was safe and generally well tolerated, and demonstrated modest efficacy in reducing the severity of filamentary keratitis. These results should be considered preliminary; however, placebo-controlled investigations would be justified to evaluate the therapeutic efficacy of oral guaifenesin as a mucolytic in treatment of filamentary keratitis.},
	issn = {1937-5913},
	doi = {10.1016/j.jtos.2019.03.008},
	author = {Coco, Giulia and Amparo, Francisco and Patel, Sangita P and Foulsham, William and Carreno-Galeano, Jimena Tatiana and Stockslager, Steven G and Ciolino, Joseph B and Yin, Jia and Dana, Reza}
}
